Literature DB >> 17523751

Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

S D Walter1, Amiram Gafni, Stephen Birch.   

Abstract

Various methods have been proposed to address uncertainty in economic evaluations of healthcare programmes. One approach suggested in the literature is to estimate separate confidence intervals for the incremental costs and effects of a new health programme in comparison with an existing programme. These intervals are then combined to generate a rectangular confidence region in the cost-effectiveness plane that implicitly defines a corresponding confidence interval for the incremental cost-effectiveness ratio (ICER). The same approach has been used to calculate sample sizes and study power. This application of the rectangle method is consistent with the adoption of ICERs and a threshold as a decision rule, this being the most commonly used approach in empirical applications of cost-effectiveness analysis, as well as the one recommended by agencies that assess medical technology around the world. In this paper, we first outline the rectangle method, and then propose a modification that recognises that separate inferences are being drawn on the cost and effectiveness domains, and that corrects for multiple statistical comparisons. The confidence rectangle is otherwise too small, the corresponding confidence interval for the ICER is too narrow and sample sizes are under-estimated. Our modification corrects these problems. A further difficulty is that the placement of the confidence rectangle around the null value is somewhat arbitrary, and does not correspond to a unique value of ICERs. As a result, different values of sample size and power for the estimation of ICERs can be obtained, depending on the null values of the cost and effectiveness. We conclude that it is important to clearly identify the analytic goal in terms of estimating differential costs, differential effects or a combination of the two using the ICER index. These ideas are illustrated using numerical examples.

Mesh:

Year:  2007        PMID: 17523751     DOI: 10.2165/00019053-200725060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

1.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  Is there a kink in consumers' threshold value for cost-effectiveness in health care?

Authors:  Bernie J O'Brien; Kirsten Gertsen; Andrew R Willan; Lisa A Faulkner
Journal:  Health Econ       Date:  2002-03       Impact factor: 3.046

3.  On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Health Econ       Date:  2002-04       Impact factor: 3.046

Review 4.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.

Authors:  Andrew H Briggs; Bernie J O'Brien; Gordon Blackhouse
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

5.  Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.

Authors:  A R Willan; B J O'Brien
Journal:  Health Econ       Date:  1999-05       Impact factor: 3.046

6.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

7.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 9.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

10.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods.

Authors:  D Polsky; H A Glick; R Willke; K Schulman
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

View more
  1 in total

1.  Evaluating the Financial Sustainability of the School-Based Telemedicine Asthma Management Program.

Authors:  Christina Crabtree-Ide; Denise F Lillvis; Jing Nie; Maria Fagnano; Reynaldo S Tajon; Paul Tremblay; Jill S Halterman; Katia Noyes
Journal:  Popul Health Manag       Date:  2021-05-14       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.